NCT07036029View on ClinicalTrials.gov

NAL ER IPF Respiratory Function and Safety Study

PHASE1RecruitingINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

September 30, 2025

Study Completion Date

October 31, 2025

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG

NAL ER

Oral tablets

DRUG

Placebo

Oral tablets

Trial Locations (2)

55905

NOT_YET_RECRUITING

Mayo Clinic, Rochester

M23 9QZ

RECRUITING

Medicines Evaluation Unit Ltd., Manchester

Sponsors

Lead Sponsor

Trevi Therapeutics

All Listed Sponsors

lead

Trevi Therapeutics

INDUSTRY